Literature DB >> 17416265

Renin-angiotensin system and cardiovascular risk.

Roland E Schmieder1, Karl F Hilgers, Markus P Schlaich, Bernhard M W Schmidt.   

Abstract

The renin-angiotensin system is a major regulatory system of cardiovascular and renal function. Basic research has revealed exciting new aspects, which could lead to novel or modified therapeutic approaches. Renin-angiotensin system blockade exerts potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of the system-ie, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are now first-line treatments for hypertensive target organ damage and progressive renal disease. Their effects are greater than expected by their ability to lower blood pressure alone. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke. Renin-angiotensin system blockade delays or avoids the onset of type 2 diabetes and prevents cardiovascular and renal events in diabetic patients. Thus, blockade of this system will remain a cornerstone of our strategies to reduce cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416265     DOI: 10.1016/S0140-6736(07)60242-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  166 in total

Review 1.  Sodium-to-potassium ratio and blood pressure, hypertension, and related factors.

Authors:  Vanessa Perez; Ellen T Chang
Journal:  Adv Nutr       Date:  2014-11-14       Impact factor: 8.701

2.  Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats.

Authors:  Jian Yang; Caiyu Chen; Hongmei Ren; Yu Han; Duofen He; Lin Zhou; Ulrich Hopfer; Pedro A Jose; Chunyu Zeng
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

3.  The frail renin-angiotensin system.

Authors:  Peter M Abadir
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

4.  Management of the metabolic syndrome in cardiovascular disease.

Authors:  Wai Ping Alicia Chan; Aaron Leonid Sverdlov; John David Horowitz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-02

5.  Aliskiren (tekturna), a novel antihypertensive approach to inhibition of the Renin-Angiotensin-aldosterone system.

Authors:  Julie Cromer; Simona Peker
Journal:  P T       Date:  2008-02

6.  Increased urinary angiotensinogen is an effective marker of chronic renal impairment in very low birth weight children.

Authors:  Naoto Nishizaki; Daishi Hirano; Yuji Nishizaki; Shuichiro Fujinaga; Satoru Nagata; Yoshiyuki Ohtomo; Kazunari Kaneko; Toshiaki Shimizu
Journal:  Clin Exp Nephrol       Date:  2013-11-01       Impact factor: 2.801

7.  Polymorphisms in the renin-angiotensin system and migraine in women.

Authors:  Markus Schürks; Robert Y L Zee; Julie E Buring; Tobias Kurth
Journal:  Headache       Date:  2008-10-27       Impact factor: 5.887

8.  Cardiac steatosis potentiates angiotensin II effects in the heart.

Authors:  Denis J Glenn; Michelle C Cardema; Wei Ni; Yan Zhang; Yerem Yeghiazarians; Dmitry Grapov; Oliver Fiehn; David G Gardner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

Review 9.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

Review 10.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.